A detailed history of Janus Henderson Group PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 59,840 shares of IBRX stock, worth $289,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,840
Previous 60,526 1.13%
Holding current value
$289,027
Previous $325,000 16.31%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.82 - $9.15 $3,306 - $6,276
-686 Reduced 1.13%
59,840 $378,000
Q1 2024

May 15, 2024

BUY
$3.23 - $6.17 $35 - $67
11 Added 0.02%
60,526 $325,000
Q4 2023

Feb 14, 2024

SELL
$1.25 - $5.21 $1 - $5
-1 Reduced -0.0%
60,515 $303,000
Q3 2023

Nov 14, 2023

BUY
$1.29 - $3.1 $43 - $105
34 Added 0.06%
60,516 $102,000
Q2 2023

Aug 14, 2023

BUY
$1.53 - $6.41 $240 - $1,006
157 Added 0.26%
60,482 $168,000
Q1 2023

May 15, 2023

BUY
$1.35 - $4.78 $38,749 - $137,200
28,703 Added 90.77%
60,325 $109,000
Q3 2022

Nov 14, 2022

SELL
$3.65 - $6.43 $6,745 - $11,882
-1,848 Reduced 5.52%
31,622 $157,000
Q2 2022

Aug 15, 2022

BUY
$2.68 - $6.14 $89,699 - $205,505
33,470 New
33,470 $125,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.93B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.